Prevalence of inhibitors and clinical characteristics in patients with haemophilia in a middle-income Latin American country
- 1 March 2020
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 26 (2), 290-297
- https://doi.org/10.1111/hae.13951
Abstract
Introduction Development of inhibitors is the most serious complication in patients with haemophilia (PWH). The prevalence of inhibitors in patients with severe haemophilia A (HA) is approximately 25%-30%. Inhibitor prevalence differs among populations. Some studies report a prevalence of almost twice in Hispanic as compared to Caucasian patients. Most data available, on the prevalence of inhibitors and their predisposing factors, originate from centres in developed countries. Aim Establish the prevalence of inhibitors of FVIII and FIX in Mexico. Methods This was an observational, cross-sectional and descriptive study. The records of all patients diagnosed with haemophilia A (HA) or B (HB), with and without inhibitors, were included. Clinical and demographical characteristics of patients with inhibitors were assessed. Statistical analysis was performed using IBM SPSS version 22. The Ethics Committees of the various participating institutions approved this study. Results A total of 1455 patients from the 20 participating centres were recruited, from which 1208 (83.02%) had HA and 247 (16.97%) were diagnosed with HB. The presence of inhibitors in severe HA was reported in 93/777(11.96%), and 10/162 (6.17%) in severe HB. Of them, 91.7% exhibited high titres in HA and 100% in HB. Conclusion In Mexico, the general prevalence of inhibitors varies considerably among centres. This study established a basis of comparison for future development and advances in the treatment and follow-up of patients. These findings also augment our understanding of risk factors related to inhibitor development.This publication has 39 references indexed in Scilit:
- F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined CohortHaemophilia, 2012
- Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection databaseHaemophilia, 2012
- F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicityHaemophilia, 2011
- Low prevalence of inhibitor antibodies in the Canadian haemophilia populationHaemophilia, 2011
- The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia AHaemophilia, 2010
- Haemophilia in SpainHaemophilia, 2009
- Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia ABlood, 2006
- Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study GroupBlood, 2003
- The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor developmentHaemophilia, 2001